Author: GlobeNewswire

Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of virusesBrilacidin is currently undergoing Phase 2…

OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed…

SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology company harnessing the power of the body’s…

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the…

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on…

Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022 SEATTLE, April 07, 2021…

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed…

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and…